Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2

BACKGROUND: Gastrointestinal stromal tumors (GISTs) are the prevailing sarcomas of the gastrointestinal tract. Tyrosine kinase inhibitors (TKIs) therapy, exemplified by Imatinib mesylate (IM), constitutes the established adjuvant therapy for GISTs. Nevertheless, post-treatment resistance poses a cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yu, Weng, Zuyi, Zhou, Xuan, Xu, Zhi, Cao, Bei, Wang, Bin, Li, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040136/
https://www.ncbi.nlm.nih.gov/pubmed/36966336
http://dx.doi.org/10.1186/s12967-023-04063-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040136/
https://www.ncbi.nlm.nih.gov/pubmed/36966336
http://dx.doi.org/10.1186/s12967-023-04063-0

Ejemplares similares